ASBMR Symposium: The Effects of Diabetes and Disordered Energy Metabolism on Skel

ASBMR 研讨会：糖尿病和能量代谢紊乱对骨骼的影响

• 批准号: 8785584
• 负责人: ANN V SCHWARTZ
• 金额: $ 3.8万
• 依托单位: AMERICAN SOCIETY FOR BONE & MINERAL RES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-13 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8785584
• 关键词: 2,4-thiazolidinedione; Accounting; Address; Advanced Glycosylation End Products; Affect; Age; Antidiabetic Drugs; Area; Awareness; Basic Science; Biochemical Markers; Biology; Blood Vessels; Clinical; Clinical Management; Clinical Medicine; Clinical Research; Collaborations; Collagen; Communication; Data; Development; Diabetes Mellitus; Diagnosis; Disease; Elderly; Energy Metabolism; Epidemiology; Excess Mortality; Fracture; Gastrointestinal Hormones; Glucagon; Glucose; Goals; Health; Hip Fractures; Homeostasis; Hormones; Hospitalization; Human; Insulin; Insulin Resistance; Insulin-Dependent Diabetes Mellitus; Interdisciplinary Study; Investigation; Life; Life Expectancy; Mind; Morbidity - disease rate; Non-Insulin-Dependent Diabetes Mellitus; Osteocalcin; Osteoporosis; PPAR gamma; Patients; Peptides; Pharmaceutical Preparations; Population; Pre-Clinical Model; Prediabetes syndrome; Process; Property; Proteins; Public Health; Research; Research Personnel; Risk; Risk Assessment; Risk Estimate; Risk Factors; Skeleton; Thiazolidinediones; Treatment Cost; Walking; age group; base; bone; bone cell; bone metabolism; bone quality; cost; diabetic; diabetic patient; experience; high risk; improved; meetings; posters; public health relevance; skeletal; symposium; tool; translational medicine

DESCRIPTION (provided by applicant): In the U.S., 2 million older adults experience a fracture annually with treatment costs of $17 billion. Those with type 1 or type 2 diabetes have an increased fracture risk. Thus, the morbidity from fractures, already identified as an important public health issue in the broader population of older adults, is even more prevalent among those with diabetes. The quality of diabetic bone is compromised but the reasons for this are not understood, impeding the ability to diagnose and treat osteoporosis in diabetic patients. Current clinical tools under- estimate fracture risk in diabetic patients, and the goal of improving risk assessment has spurred investigations into biochemical markers, microstructure and material properties of diabetic bone. There is increasing awareness that diabetes medications may have skeletal effects. This is a crucial juncture and opportunity for research into the effects of disordered energy metabolism on bone. Advances are being made in the clinical and basic biology arenas. However, progress is hampered by the lack of venues for communication across bone and energy metabolism research and by separations among investigators in basic science, epidemiology, and translational and clinical medicine. This symposium will provide a venue for interaction at the meeting itself and through dissemination of post-meeting summaries, reaching well beyond those in attendance and bringing a new level of maturity to this research. The specific aims are 1) To present the latest research on the effects of disordered energy metabolism and diabetes on bone biology, including effects on bone cells, material properties and microstructure, 2) To present the latest research on the diagnosis and management of osteoporosis in patients with diabetes and on the potential skeletal effects of diabetes treatments and 3) To promote interaction among basic, translational and clinical researchers in osteoporosis and diabetes research. The symposium will provide opportunities for interactions and collaborations at the poster sessions, during lunch and through a dine-around for young and senior investigators. The aims will be accomplished by inviting internationally known researchers to present their latest data on advances in understanding insulin resistance, lessons from preclinical models of diabetes and bone, human bone metabolism in diabetes, the effects of diabetic medications on bone, the limitations of FRAX in diabetic patients and diabetes-related risk factors for fracture, and pharmacological therapies for osteoporosis in diabetic patients. The symposium will conclude with a panel of clinical experts addressing "Clinical management: what is known and where is more research needed?" Attendees will be encouraged to attend the ASBMR 2014 Annual Meeting following the symposium and vice versa. Support will be provided to encourage young investigators to attend. The symposium will generate a better understanding of diabetes and bone, bridge the gaps among investigators in the basic science, translational and clinical arenas, increase communication and interaction among investigators in bone and in energy metabolism, and provide significant maturation for this crucial area of research.

描述(由申请人提供)：在美国，每年有200万老年人经历骨折，治疗费用为170亿美元。那些患有1型或2型糖尿病的人骨折风险增加。因此，在更广泛的老年人中，骨折的发病率已经被确定为一个重要的公共卫生问题，在糖尿病患者中甚至更加普遍。糖尿病患者的骨骼质量受损，但其原因尚不清楚，阻碍了糖尿病患者诊断和治疗骨质疏松症的能力。目前的临床工具低估了糖尿病患者的骨折风险，改进风险评估的目标促使人们对糖尿病骨的生化标记物、微观结构和材料特性进行研究。人们越来越意识到糖尿病药物可能会对骨骼产生影响。这是研究能量代谢紊乱对骨骼影响的关键时刻和机会。在临床和基础生物学领域正在取得进展。然而，由于缺乏跨骨骼和能量代谢研究的交流场所，以及基础科学、流行病学、转化医学和临床医学的研究人员之间的分离，进展受到阻碍。这次专题讨论会将提供一个在会议本身和通过传播会后总结进行互动的场所，远远超出出席者的范围，并使这项研究达到一个新的成熟水平。具体目的是1)介绍能量代谢紊乱和糖尿病对骨生物学的影响的最新研究，包括对骨细胞、材料特性和微结构的影响；2)介绍糖尿病患者骨质疏松症的诊断和治疗以及糖尿病治疗的潜在骨骼影响的最新研究；3)促进基础、翻译和临床研究人员在骨质疏松症和糖尿病研究方面的互动。研讨会将为青年和高级调查人员在招贴会议、午餐期间和聚餐时提供互动和合作的机会。这些目标将通过邀请国际知名的研究人员介绍他们在了解胰岛素抵抗方面的最新数据，糖尿病和骨骼的临床前模型的教训，糖尿病患者的骨代谢，糖尿病药物对骨骼的影响，糖尿病患者FRAX的局限性和糖尿病相关的骨折危险因素，以及治疗糖尿病的药物治疗。 糖尿病患者的骨质疏松症。研讨会结束时，临床专家小组将讨论“临床管理：已知的是什么，需要在哪里进行更多的研究？”将鼓励与会者在研讨会之后参加ASBMR 2014年会，反之亦然。将提供支持，鼓励年轻调查人员参加。研讨会将增进对糖尿病和骨骼的了解，弥合研究人员在基础科学、翻译和临床领域的差距，加强研究人员在骨骼和能量代谢方面的交流和互动，并为这一关键研究领域提供显著的成熟。